keyword
MENU ▼
Read by QxMD icon Read
search

Advanced prostate cancer

keyword
https://www.readbyqxmd.com/read/28737470/recent-advances-in-circulating-tumor-cells-and-cell-free-dna-in-metastatic-prostate-cancer-a-review
#1
Sunil Parimi, Jenny J Ko
The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there is a heightened urgency to develop biomarkers that can guide prognoses and predict therapy responses. Circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) in the blood have emerged as potential promising tumor avatars. Areas covered: In this review, we describe technological breakthroughs and clinical implementation of the CTCs and ctDNA...
July 24, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28736082/differential-proteome-expression-analysis-of-androgen-dependent-and-independent-pathways-in-lncap-prostate-cancer-cells
#2
Seho Cha, Dong Hoon Shin, Jun Ryeong Seok, Jae Kyung Myung
Prostate cancer (PC) is one of the leading causes of cancer death in men. It commonly develops in older males, but the number of younger men diagnosed with the disease has increased in recent years. Hormone therapies, such as chemical and surgical methods that inhibit androgen synthesis or androgen receptor (AR) activation, have been used for advanced disease. However, castration-resistant PC (CRPC), which exhibits androgen-independent mechanisms for activating AR, develops after a few years of such treatment and no therapy is available...
July 20, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28734596/developments-in-urologic-oncology-%C3%A2-oncoforum%C3%A2-the-best-of-2016
#3
F Gómez-Veiga, A Alcaraz-Asensio, J Burgos-Revilla, J M Cózar-Olmo
OBJECTIVE: To put forth new findings of urologic oncology with impact on clinical practice presented during 2016 in the main annual meetings. ACQUISITION OF EVIDENCE: This document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee. SYNTHESIS OF EVIDENCE: In High-Risk Renal-Cell carcinoma after nephrectomy, disease-free survival was significantly greater for sunitinib than placebo group, with adverse events more frequents...
July 19, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28733088/treating-advanced-prostate-cancer-the-human-factor
#4
EDITORIAL
Megan E V Caram, David C Miller
No abstract text is available yet for this article.
July 18, 2017: European Urology
https://www.readbyqxmd.com/read/28730423/-female-prostate-cancer
#5
S Thum, B Haben, G Christ, R Sen Gupta
We present a case of a female patient who had a clinically suspected advanced urothelial carcinoma of the urethra. Histopathological examination surprisingly revealed a malignant tumor with morphological and immunohistochemical features of prostate cancer, leading to the diagnosis of the extremely rare entity of Skene's gland adenocarcinoma.
July 20, 2017: Der Pathologe
https://www.readbyqxmd.com/read/28730245/unusual-triple-combination-of-prostate-lung-and-skin-cancer
#6
Ioana Andreea Gheonea, Cristiana Gabriela Popp, Elena Tatiana Ivan, Dan IonuŢ Gheonea
Multiple malignancies are an increasing combination in the recent years in cancer patients, due to prolonged survival rate and to the advances in diagnostic techniques and therapeutic management. We present the case of a patient diagnosed with prostate cancer and metachronous in one year with basal cell carcinoma of the skin and small lung cell carcinoma with lymph nodes and pararectal metastasis. To our best knowledge, this is the only case presented in the medical literature with these three different types of primary malignancy...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/28726527/the-comparison-and-estimation-of-the-prognostic-value-of-lipid-profiles-in-patients-with-prostate-cancer-depends-on-cancer-stage-advancement
#7
Edyta Idalia Wolny-Rokicka, Andrzej Tukiendorf, Jerzy Wydmański, Agnieszka Zembroń-Łacny
Lipid profiles and prostate cancer have a controversial relationship, and the predictive ability of lipids in determining cancer risk estimation is still questionable. This study demonstrates a significance assessment of the plasma lipid profiles of subjects with prostate cancer. Locoregional subjects irradiated with external beam therapy were compared to prostate cancer subjects with bone metastases. The histopathologic diagnosis of 103 subjects (71 locoregional [Group 1] and 32 palliative [Group 2]) were analyzed and compared using their blood samples, total cholesterol (CHL), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol...
July 1, 2017: American Journal of Men's Health
https://www.readbyqxmd.com/read/28725597/canine-prostate-models-in-preclinical-studies-of-minimally-invasive-interventions-part-i-canine-prostate-anatomy-and-prostate-cancer-models
#8
REVIEW
Fei Sun, Claudia Báez-Díaz, Francisco Miguel Sánchez-Margallo
The high prevalence of prostate cancer (PCa) in elderly men and technical advances in early detection of localized PCa have led to continued efforts to develop new therapeutic options of minimally invasive nature in current urologic oncology community. Increasing newly emerging therapies are undergoing preclinical tests on the technical feasibility, efficacy and safety in animal experiments. The dog is an ideal large animal because of its similar anatomy to human and the capability allowing the use of the same medical devices applied in future clinical trials...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725591/diffusion-weighted-imaging-of-the-prostate-principles-application-and-advances
#9
REVIEW
Martin H Maurer, Johannes T Heverhagen
This review article aims to provide an overview on the principles of diffusion-weighted magnetic resonance imaging (DW-MRI) and its applications in the imaging of the prostate. DW-MRI with regards to different applications for prostate cancer (PCa) detection and characterization, local staging as well as for active surveillance (AS) and tumor recurrence after radical prostatectomy (RP) will be discussed. Furthermore, advances in DW-MRI techniques like diffusion kurtosis imaging (DKI) will be presented.
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725590/mri-fusion-biopsy-the-contemporary-experience
#10
REVIEW
Marc A Bjurlin, Andrew B Rosenkrantz, Samir S Taneja
Advancements in magnetic resonance imaging (MRI) and MRI-ultrasound (US)-fusion targeted biopsy have resulted in a paradigm shift in the diagnosis of prostate cancer by overcoming the limitations of systematic biopsy. Prebiopsy MRI and MRI-US-fusion biopsy results in an increased detection of clinically significant disease, reduction in the detection of indolent disease, and allows for tumor localization during targeted biopsy. With these advantages, we have adopted a prebiopsy MRI and MRI-US-fusion biopsy diagnostic care pathway for all men at risk for prostate cancer and have performed more than 1900 biopsies to date...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725580/pre-biopsy-mri-as-an-adjunct-for-cancer-detection-in-men-with-elevated-psa-and-no-previous-biopsy
#11
REVIEW
Facundo Uriburu-Pizarro, Veeru Kasivisvanathan, Philippe Puech, Arnauld Villers
The role of magnetic resonance imaging (MRI) prior to biopsy in the diagnosis of prostate cancer in biopsy-naïve patients has been strengthened by recent developments such as the PIRADS V2 criteria, which cover acquisition, interpretation, and reporting for clinical practice and data collection for research. Important questions on the role of prostate MRI remain: can MRI be used as a triage test before first biopsy series? Can it be used to avoid the use of systematic biopsies (SB) and instead use only targeted biopsies (TB) to MRI-suspicious lesions? Studies to evaluate image guided TB compared to SB have started to accumulate...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725579/multiparametric-magnetic-resonance-imaging-of-the-prostate-a-basic-tutorial
#12
REVIEW
Miguel C Cabarrus, Antonio C Westphalen
Prostate cancer is the second most common cause of cancer related death in the United States and the most commonly diagnosed malignancy in men. In general, prostate cancer is slow growing, though there is a broad spectrum of disease that may be indolent, or aggressive and rapidly progressive. Screening for prostate is controversial and complicated by lack of specificity and over diagnosis of clinically insignificant cancer. Imaging has played a role in diagnosis of prostate cancer, primarily through systemic transrectal ultrasound (TRUS) guided biopsy...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28723656/inhibitor-of-h3k27-demethylase-jmjd3-utx-gsk-j4-is-a-potential-therapeutic-option-for-castration-resistant-prostate-cancer
#13
Viacheslav M Morozov, Ying Li, Matthew M Clowers, Alexander M Ishov
Androgen receptor (AR) mediates initiation and progression of prostate cancer (PCa); AR-driven transcription is activated by binding of androgens to the ligand-binding domain (LBD) of AR. Androgen ablation therapy offers only a temporary relief of locally advanced and metastatic PCa, and the disease eventually recurs as a lethal castration-resistant PCa (CRPC) as there is no effective treatment for CRPC patients. Thus, it is critical to identify novel targeted and combinatorial regimens for clinical management of CRPC...
July 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28723521/bone-scan-index-and-progression-free-survival-data-for-progressive-metastatic-castration-resistant-prostate-cancer-patients-who-received-odm-201-in-the-arades-multicentre-study
#14
Mariana Reza, Robert Jones, John Aspegren, Christophe Massard, Leena Mattila, Mika Mustonen, Per Wollmer, Elin Trägårdh, Eva Bondesson, Lars Edenbrandt, Karim Fizazi, Anders Bjartell
BACKGROUND: ODM-201, a new-generation androgen receptor inhibitor, has shown clinical efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess changes in bone as a measurement of treatment response. The Bone Scan Index (BSI) reflects the percentage of skeletal mass a given tumour affects. OBJECTIVE: To evaluate the predictive value of the BSI in metastatic castration-resistant PCa (mCRPC) patients undergoing treatment with ODM-201...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723516/the-molecular-evolution-of-castration-resistant-prostate-cancer
#15
REVIEW
Yvonne Ceder, Anders Bjartell, Zoran Culig, Mark A Rubin, Scott Tomlins, Tapio Visakorpi
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably develops through a range of different molecular mechanisms accompanied by progression to a more aggressive phenotype. OBJECTIVE: To understand the key molecular mechanisms leading to CRPC and the functional implications of this progression. Understanding molecular evolutionary mechanisms in CRPC is essential for the development of novel curative therapeutic approaches...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723512/palliative-radical-cysto-prostatectomy-for-locally-advanced-symptomatic-castration-resistant-prostate-cancer
#16
Axel Heidenreich
Palliative radical (cysto-)prostatectomy is associated with a median symptom-free survival which covers 75-80% of the remaining lifetime in patients with symptomatic locally advanced castration-resistant prostate cancer.
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723506/biomarkers-for-metastatic-castration-resistant-prostate-cancer-mcrpc-yes-or-no-predictive-and-response-biomarkers-towards-precision-medicine-in-mcrpc
#17
Joaquin Mateo
Advances in drug development and molecular studies for castration-resistant prostate cancer (CRPC) render the possibility of more efficient and precise patient care through the use of predictive, response, and resistance biomarkers. Thorough scrutiny of assay validation and clinical qualification processes for biomarkers in development, ideally in parallel with clinical trials, is critical for the success of personalised medicine in CRPC management.
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28722438/graphene-oxide-upconversion-nanoparticle-based-optical-sensors-for-targeted-detection-of-mrna-biomarkers-present-in-alzheimer-s-disease-and-prostate-cancer
#18
Patrick Vilela, Afaf El-Sagheer, Timothy M Millar, Tom Brown, Otto L Muskens, Antonios G Kanaras
The development of new sensors for the accurate detection of biomarkers in biological fluids is of utmost importance for the early diagnosis of diseases. Next to advanced laboratory techniques, there is a need for relatively simple methods which can significantly broaden the availability of diagnostic capability. Here, we demonstrate the successful application of a sensor platform based on graphene oxide and upconversion nanoparticles (NPs) for the specific detection of mRNA-related oligonucleotide markers in complex biological fluids...
January 27, 2017: ACS Sensors
https://www.readbyqxmd.com/read/28722437/surface-plasmon-resonance-clinical-biosensors-for-medical-diagnostics
#19
Jean-Francois Masson
The design and application of sensors for monitoring biomolecules in clinical samples is a common goal of the sensing research community. Surface plasmon resonance (SPR) and other plasmonic techniques such as localized surface plasmon resonance (LSPR) and imaging SPR are reaching a maturity level sufficient for their application in monitoring biomolecules in clinical samples. In recent years, the first examples for monitoring antibodies, proteins, enzymes, drugs, small molecules, peptides, and nucleic acids in biofluids collected from patients afflicted with a series of medical conditions (Alzheimer's, hepatitis, diabetes, leukemia, and cancers such as prostate and breast cancers, among others) demonstrate the progress of SPR sensing in clinical chemistry...
January 27, 2017: ACS Sensors
https://www.readbyqxmd.com/read/28721912/exosomes-and-exosomal-micrornas-in-prostate-cancer-radiation-therapy
#20
REVIEW
Bijaya Malla, Kathrin Zaugg, Erik Vassella, Daniel M Aebersold, Alan Dal Pra
Despite current risk stratification systems using traditional clinicopathologic factors, many localized and locally advanced prostate cancers fail radical treatment (ie, radical prostatectomy, radiation therapy with or without androgen deprivation therapy). Therefore, a pressing need exists for enhanced methods of disease stratification through novel prognostic and predictive tools that can reliably be applied in clinical practice. Exosomes are 50- to 150-nm small vesicles released by cancer cells that reflect the genetic and nongenetic materials of parent cancer cells...
August 1, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
45030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"